ABSTRACT
For antibody-based drugs, it is important and relevant to study their toxic effects, which can often become limiting when prescribing this type of therapy. General toxicity of antiviral drug Ergoferon based on technologically processed antibodies was studied on sexually mature animals. Analysis of acute toxicity showed the absence of lethal outcomes when the drug was administered to adult rats at the maximum tolerated doses. In a study of repeated dose toxicity, no adverse effects of the drug were detected.
Subject(s)
Antibodies , Antiviral Agents , Rats , Animals , Antiviral Agents/pharmacology , Antibodies/pharmacology , Toxicity Tests, AcuteABSTRACT
We studied the ability of technologically processed antibodies to the brain-specific S100 protein (drug Prospekta) to reduce the brain lesion area, neurological disorders, and mortality in a rat model of hemorrhagic stroke. Technologically processed antibodies to S100 exerted a positive effect on all these parameters (brain lesion area, survival rate, neurological status according to the Menzies scale, and proportion of contralateral turns). This allows us to recommend further research into the spectrum of pharmacological activity and the mechanism of action of technologically processed antibodies to S100 in order to expand the indications for their use after the necessary clinical trials.
Subject(s)
Brain Ischemia , Hemorrhagic Stroke , Stroke , Rats , Animals , S100 Proteins , BrainABSTRACT
AIM: On amnesia models induced by (icv) injection of ß-amyloid fragment 25-35 peptide were evaluated antiamnestic actitity. MATERIAL AND METHODS: It was used of active antibody preparations (RA AT) to protein S100 (tenoten), to eNOS (impaza) and combinations (divaza) antiamnestic activity behavioral tests novel object conditioned response passive avoidance. RESULTS: Under the influence of RA AT S100 observed recovery of violation of the ß-amyloid short-term memory (1 hour after the initial presentation of objects), and RA AT eNOS were more effective when tested 24 hours later. Combined medication completely compensate for the simulated deflection behavior of rats did not differ from the intact control. The CRPA RA AT S100 had the greatest impact on the LP entry into the dark compartment, and RA AT eNOS influenced primarily on the emotional component of the reaction. When using the integrated product tends to increase the LP entry into the dark compartment was observed in the absence of changes in the number of boluses. Thus, tenoten had the greatest impact on cognitive impairment, impaza greater effect on the symptoms associated with surgery. CONCLUSION: Combined preparation divaza rendered more effective action, leveling and amnesia neophobia, which confirms the need for further research and prospect release of active drugs in models of neurodegenerative disorders.
Subject(s)
Alzheimer Disease/drug therapy , Amnesia/drug therapy , Antibodies/therapeutic use , Amnesia/chemically induced , Amyloid beta-Peptides/pharmacology , Animals , Antibodies/pharmacology , Avoidance Learning/drug effects , Disease Models, Animal , Male , Memory, Short-Term/drug effects , Peptide Fragments/pharmacology , Rats , Rats, Wistar , S100 Proteins/immunologyABSTRACT
Antibodies to 5100 proteins (anti-5100) in release-active form (RA anti-5100) are an active component of some domestic drugs(tenoten, tenoten for children, divaza, brizantin, kolofort and proproten-100). The authors present the results of preclinical and clinical trials (with detailed consideration of experimental data) which demonstrated a wide spectrum of specific pharmacological activity and safety as well as mechanisms of anti-5100 action.
Subject(s)
Antibodies/pharmacology , S100 Proteins/antagonists & inhibitors , S100 Proteins/immunology , Stress, Psychological/therapy , Antibodies/adverse effects , Antibodies/therapeutic use , Clinical Studies as Topic , Drug Evaluation, Preclinical , Humans , Stress, Psychological/immunologyABSTRACT
The anxiolytic and antidepressant activities of complex preparations divaza and brizantin containing antibodies to brain-specific protein S100 were estimated using Vogel conflict test and Nomura forced swimming test. Course treatment (5 days) of brizantin in a dose of 2.5 ml/kg and divaza in a dose of 7.5 ml/kg significantly increased punished drinking in the Vogel conflict test in comparison with the control. Both drugs also improved general emotional behavior during training prior to the test procedure. Brizantin and divaza in a dose of 7.5 ml/kg increased the number of wheel revolutions in the Nomura forced swimming test in comparison with the control; the effect of divaza was more pronounced. High correlation coefficients between the number of wheel revolutions during the first and second 5-min sessions are also indicative of antidepressant action of divaza and brizantin.
Subject(s)
Anti-Anxiety Agents/pharmacology , Antibodies/pharmacology , Antidepressive Agents/pharmacology , Animals , Behavior, Animal/drug effects , Brain/drug effects , Diazepam/pharmacology , Drug Combinations , Drug Evaluation, Preclinical , Male , Maze Learning/drug effects , Motor Activity/drug effects , Rats , Stress, Psychological/pathology , Swimming/psychologyABSTRACT
AIM: To reveal the effects of release-active antibodies to S100 protein in an animal model of multiple sclerosis. MATERIAL AND METHODS: Sixty female Wistar rats, aged 12 weeks, were included in the study. The pathology was induced by subcutaneous injection of the spinal cord homogenate. Afterwards the rats received a water solution of release-active antibodies to S100 protein (2,5 ml/kg/day, tenoten) or distilled water intragastrically during 30 days. Intramuscular injections of glatiramer acetate (4 mg/kg/day, copaxone) were used as a positive control. RESULTS AND CONCLUSION: Release-active antibodies to S100 protein enhanced the latency period of the disease, reduced its peak intensity and compensated the loss of body weight of the animals. The experimental drug effect was similar to the results of copaxone injections.
